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ABSTRACT
Objective: To propose a methodology to estimate the
number of new HIV infections averted. Knowledge of HIV
infection has increased tremendously and modelling tools
to project current epidemics into the future have greatly
improved. Different types of models can be used to
estimate HIV infections averted, although the number of
new HIV infections averted cannot be measured directly.
Method: Using cohort-component population projections,
a disease modelling-based approach was used to
compare the observed epidemiology of a disease after
programme initiation with an expected epidemiology from
past trends before programme initiation. The concept of
modelling infections averted in a disease modelling-based
approach involves a comparison between an ‘‘expected’’
or baseline epidemic with an ‘‘estimated’’ one. A
hypothetical example was featured in order to demon-
strate the proposed methodology. Using both the
Estimation and Projection Package (EPP) and the
Spectrum demographic modelling program, the underlying
annual incidence levels implied by both the baseline and
estimated epidemics were examined.
Results: The difference between baseline and estimated
incidence levels is interpreted as ‘‘infections averted’’.
Strengths and limitations of the approach are discussed.
Conclusions: In this study an expected epidemiological
approach was compared to one based on observation.
Once sufficient data become available, the validation of
various country data including HIV prevalence, mortality,
and behaviour must be done. Additional information
related to behaviour change may be critical to further
support arguments for a change in disease trend. It is
therefore important to use all available data, consequently
strengthening findings from a disease modelling-based
approach on HIV infections averted.
At present, the number of people living with HIV
and AIDS continues to increase in many areas of the
world. At the same time, we have the HIV
prevention and treatment strategies and tools to
mitigate the epidemic. To meet the challenges ahead
we must continue to strengthen these. Effective
prevention and treatment activities go towards
averting potential HIV infections that would other-
wise occur. Voluntary counselling and testing,
condom social marketing, antiretroviral use and
mass media campaigns are only a few of many
strategies employed to curb HIV transmission.
In order to gauge the possible impacts of
prevention and treatment programmes, a metho-
dology must be in place to estimate HIV infections
averted. In this paper, we introduce three basic
approaches to estimate HIV infections averted.
One of the three approaches, a disease modelling-
based approach, is discussed at length.
Coverage-based approach
In this approach, estimation of new infections
averted involves estimating the possible outcome
of a proposed intervention. This estimate is typically
based on a literature review and an assumption of
theintervention’scoverage.Evaluatingtheimpactof
a health intervention on disease is of great interest in
the field of publichealth. One reasonfor thisinterest
is to advocate for certain intervention programmes
to reduce or halt the spread of a disease. Estimating
the number of infections averted attributable to
such programmes can also provide impetus to
establishing the program, help focus programme
activities, andsetgoals.
1–9 Determining howmuchto
scale up programmes to reach a larger number of
people in need of the intervention is also of
concern.
10–12 An analysis of this approach is hypothe-
tical in that we are answering questions such as ‘‘If
male circumcision rates increase by 100% over a
specific period of time, whatare the possible number
of HIV infections that might be averted over that
time period?’’ Thus, the coverage-based approach
can be valuable for public health advocacy purposes.
Behaviour-based approach
HIV infections are mediated by behaviour with
interventions intended to change risky behaviours.
A model can be constructed to evaluate these
interventions for their effectiveness. This is known
as a ‘‘behaviour-based approach’’, as HIV infections
are mediated by behaviour with interventions aimed
at changing risky behaviours.
13–15 Most available
interventions intend to reduce risky behaviours,
thereby reducing new infections. Thus, if the effect
of a behaviour change on new infections and the
prevalence of changed behaviour are known (or
assumed), mathematical models can be constructed
based on behaviour. However, the relation between
behaviour and disease is complex and dependent on
the epidemiological context.
15 16 Cost-effectiveness
analysis of intervention programmes often occurs in
both the coverage-based and behaviour-based
approacheswhen selecting or advocating for a certain
intervention.
4 7–9 11 13 14 A major problem with the
behaviour-based approach is that there is a clear lack
of relevant behavioural data to use in many develop-
ing countries, although there have been an increasing
number of behavioural surveys. Therefore, the
behaviour-based approach is difficult to implement
currently in any reliable way in most developing
countries.
Disease modelling-based approach
In this approach, the observed epidemiology of a
disease after intervention can be compared with its
past epidemiology or an expected epidemiology
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demonstrate the effect of a vaccination programme by showing
a secular trend before and after introduction of the programme.
17
In all three approaches, coverage, disease and behaviour, the
number of infections averted needs to be estimated through
mathematical modelling since it cannot be measured directly
(that is, by definition, it is a non-event). Many studies in the
coverage-based and behaviour-based approaches focus on the
hypothetical analysis of the effect of certain interventions on
disease trends. However, reliance on actual epidemiological
change and an attempt to directly estimate infections averted
based on the actual epidemiology makes the disease modelling-
based approach preferable. A disease modelling-based approach
for HIV infections averted is inherently theoretical, unlike
control of endemic disease through biomedical solutions such as
immunisation. It is of special importance, therefore, to validate
and alter baseline curves based on the best available data in a
disease modelling-based approach.
Inthispaper, wefocusonthe diseasemodelling-basedapproach
to estimating new HIV infections averted. In brief, baseline
projections of HIV incidence are prepared for countries using data
pertaining to the time period before intervention programmes
were instituted. This baseline will serve as a reference for future
comparisons. In this paper, we use data for years through 2004 to
derive the baseline projection.
18 Subsequently, the incidence trend
will be re-estimated for countries using additional epidemiological
surveillance data available for years post-2004. The re-estimated
incidence trend, compared to the baseline trend,willrepresent the
change in the epidemic that may be the result of a number of
factors including programme changes. The difference in the
number of new HIV infections implied by the prevalence levels
will be taken as the number of infections averted.
We examined several countries with sentinel surveillance data
for years 2005 and 2006 and found that in the case of one of
those countries, only a few thousand HIV infections were
averted by 2010. In another country, no new HIV infections
were averted. Still, in another country, there were more
infections in the re-estimated trend than there were in the
baseline projection. To properly estimate infections averted, we
need a sufficient number of years’ worth of data post-2004 to
gauge impacts. The major obstacle in carrying out this
methodology with country-specific data is that insufficient
sentinel surveillance data are available beyond 2004 to make this
feasible at present. Validation of the results of the methodology
proposed in this paper must await further data. Therefore, we
demonstrate this model by illustrating a hypothetical example.
Applications of such a modelling approach are discussed along
with issues relevant to using this approach.
METHODOLOGY
The modelling process begins with undertaking an extensive
review of data that contain information on epidemiology,
population, fertility, mortality and migration. Sources include
census and survey data, refugee and labour migration statistics,
vital registration statistics, administrative records and HIV
surveillance data. Once this review is complete, the new
information is reconciled with the historical information. A
decision is then made on whether a revision of previous
population estimates and projections is warranted.
Although it has been clear for a number of years that
mortality estimates and projections for many countries would
have to be revised because of AIDS mortality, the lack of
accurate empirical data on AIDS deaths, the paucity of data on
HIV infection among the general population and the absence of
tools to project the impact of AIDS epidemics into the future
have all hampered these efforts. Although the accuracy of data
on AIDS cases and AIDS deaths has not substantially improved,
our knowledge of HIV infection has increased tremendously and
modelling tools to project current epidemics into the future
have greatly improved.
Development of adult HIV prevalence estimates
The Estimation and Projection Package (EPP) computer soft-
ware is used to estimate and project adult (15–49) HIV
prevalence from sentinel surveillance data in countries with
generalised epidemics, defined as an epidemic with national-
level prevalence above 1%.
19–21
In countries with a generalised epidemic, national estimates
of HIV prevalence are typically based on data generated by
surveillance systems that focus on pregnant women who attend
a sample of sentinel antenatal clinics. Typically, an urban and a
rural epidemic are derived, as the epidemics are normally
distinct in most settings. The EPP software will then aggregate
these two sub-epidemics to the national level. The national level
results are used to obtain HIV prevalence and incidence curves
used in estimation of HIV infections averted.
This method assumes that prevalence among pregnant women
is a good approximation of prevalence among the adult
population aged 15-49 in countries with a generalised HIV
epidemic.
22 National population-based studies that include HIV
testing have been completed in several countries in recent years.
23–
25Comparisonoftheseresultswiththosefromtheantenatalclinic
data has provided evidence that the use of antenatal clinic data to
model the epidemic among the adult population is appropri-
ate.
22 23 26–28 There are some recent examples of considerably lower
national HIV prevalence from population-based surveys, such as
in Kenya. Results from these population-based surveys can be
used in the EPP software to calibrate the urban and rural curves of
HIV prevalence based on antenatal data to a nationally
representative total prevalence level.
20
Development of the baseline projection
Several stages are involved in the development of the baseline
projection. First, hypothetical demographic estimates are pre-
pared that do not include AIDS mortality. The impact of the
HIV epidemic is then modelled. Estimates of AIDS mortality are
combined with the estimates of non-AIDS mortality to obtain
the baseline demographic estimates.
Hypothetical demographic results that do not include AIDS-
related mortality are produced using the Spectrum modelling
program (The Futures Institute, Glastonbury, CT, USA).
The hypothetical series shows what would have happened if
a country had not been affected by the HIV/AIDS epidemic.
This modelling takes into account not only lower death rates
but also associated changes to a country’s age-sex structure and,
indirectly, the combined effects of lower mortality and changing
population composition on demographic indicators. This series
assumes the same fertility rates (based on observed data) as the
series that incorporates HIV/AIDS. The non-AIDS results are
then input into the AIDS impact module (AIM) of Spectrum
along with the trend in HIV prevalence from EPP and other
epidemiological parameters. The estimates of incidence needed
to estimate infections averted is one of many outputs from the
Spectrum modelling program.
For ease of use, we use the 2006 revision of the World
Population Prospects from the United Nations Population
Division available in Spectrum for the demographic inputs.
29
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prevalence numbers needed for the baseline projection. Many of
the inputs used in a typical modelling exercise are those that are
based on exhaustive research by the UNAIDS modelling
group.
19 20 22 30 31 This group updates its assumptions when
additional empirical research becomes available.
DEVELOPMENT OF THE NUMBER OF INFECTIONS AVERTED
Hypothetical example
The concept of modelling infections averted in a disease
modelling-based approach involves a comparison between an
‘‘expected’’ or baseline epidemic with an ‘‘estimated’’ one. We
examine the underlying annual incidence levels implied by both
the expected and estimated epidemics. The difference in the
incidence levels is interpreted as infections averted. We use the
EPP and Spectrum models to compare fits of the data before any
major HIV programme initiatives, the baseline epidemic, and
after these initiatives have started, the estimated epidemic.
Major programme initiatives by various donors began in 2004.
As HIV prevalence data become available for the post-2004
period it is necessary to repeat the steps outlined above for the
baseline estimates to incorporate the new data. This will result
in new estimates of the number of new HIV cases for each year
from 2005 to 2010. The difference between the baseline
estimates of incidence and the post-2004 estimates is assumed
to represent the number of infections averted during the period
of interest.
We model two scenarios—a baseline projection and an
assumed 25% decline in HIV adult prevalence from the 2004
level by 2010.
In the hypothetical example of modelling infections averted,
both the number of baseline HIV infections and the resulting
incidence numbers are shown for 1995 to 2010 (fig 1).
We are primarily interested in infections averted after the
introduction of prevention programmes, 2005 in this example
(fig 2).
An estimate of infections averted after 2004, if we assume a
25% decline in HIV prevalence by 2010, would be represented in
the shaded area (fig 3). The cumulative total of the shaded area
represents the number of new infections that were averted
during the period from 2005 to 2010.
DISCUSSION
Thenumberofinfectionsavertedcannotbemeasureddirectly,but
a disease modelling-based approach is a direct estimation based on
actual data from disease surveillance systems. In contrast, a
coverage-based approach is indirect estimation based on interven-
tion coverage (hypothetical or measured) and its presumed or
estimated effect on disease. Similarly, a behaviour-based approach
is indirect estimation based on a change in prevalence of certain
behaviours and the estimated effect on a disease.
No approach can be exact since infections averted cannot be
directly measured and any models are based on a number of
assumptions. None the less, we propose a disease modelling-
based approach in this paper to estimate infections averted
because this approach is a more direct one. In addition, while we
have described estimation of HIV infections averted for
countries with generalised epidemics, this methodology can
also be used to estimate infections averted for countries with
concentrated epidemics as long as there are data to do so.
One use of estimating infections averted is to track progress
made by international initiatives. The US President’s Emergency
Plan for AIDS Relief (PEPFAR) has a global goal of seven million
HIV infections averted between the years 2005 and 2010, and a
large amount of financial resources are disbursed in PEPFAR’s 15
focus countries. Another global initiative, the Global Fund To
Fight AIDS, Tuberculosis and Malaria, also has a large
investment in HIV/AIDS programmes. In general, the impact
of donor initiatives cannot be separated in a country. Indeed,
prevention requires behavioural change along with enabling
factors such as community activities, communication, com-
modity availability and a favourable legal and environmental
framework.
32–42 In the complex environment in which HIV
prevention and treatment take place, it would be very difficult
to assess a particular programme’s impact.
Several issues related to the approach described in this paper
need to be addressed. The first is related to the time lag in the
processing and release of surveillance results. It will not be
possible to make an estimate of infections averted until well
after the post-2004 data are collected. We have observed this
when applying the methodology to specific countries. In
addition, the approach as described here can result in different
historical levels of prevalence and incidence between the
baseline scenario and the later scenario based on new HIV
prevalence data that will be used to derive infections averted—
that is, when the new HIV prevalence data post-2004 are added
to EPP, the software will often produce a somewhat different
‘‘best fit’’ of all the data, including the pre-2004 period. To
address this issue, the EPP infections-averted fitting process can Figure 1 HIV prevalence and incidence baseline scenario: 1995–2010.
Figure 2 HIV incidence—two scenarios 1995–2010.
Figure 3 Cumulative number of HIV infections averted: 2005–10.
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the infections averted period approximate the original baseline
results. This requires adjustment of any of the EPP fitting
parameters—or some sort of ratio adjustment. Another way of
addressing this issue is to limit new data entered into EPP to
only the surveillance sites available at the time the baseline
estimate was prepared (for example, only those sites available
through 2003 or 2004). However, ignoring data from new sites
added to a country’s surveillance system at a later point in time
may not be advisable. It will be important to validate the curves
to HIV prevalence, mortality, and behavioural data from several
sources once sufficient trend data are available.
Another concern is that of antiretroviral use. With wide-
spread use of these drugs in resource-constrained settings, we
could see an increase in prevalence, rather than a decline, that is
not related to an increase in incidence.
43 Although it appears
that transmissibility of HIV may be reduced among people on
antiretroviral treatment, this may be offset by increases in risk-
taking behaviour. For example, if people are feeling better as a
result of antiretroviral treatment, they may engage in more
sexual activity. However, studies have not been conclusive.
Even in industrialised settings, there is no strong evidence that
such disinhibition occurs.
44 Therefore, the increase in prevalence
due to increased survivorship of those on treatment needs to be
factored out of the infections-averted estimation process. The
next update of the EPP software will take antiretroviral use into
account in order to better fit the models.
45
Finally, in recent years, a number of countries have carried
out population-based surveys that include HIV testing and
many more are planned for the future. These surveys are finding
different levels of HIV prevalence in the general population
from that indicated by antenatal clinic sentinel surveillance. EPP
allows for the national HIV prevalence curves to be calibrated to
match the results of a population-based survey. At what point
do results represent change due to programmes and not just a
calibration to the time series? HIV prevalence itself has a range
of uncertainty and this may also need to be addressed in
infections averted.
46–48
In a stable, endemic situation, a coverage-based approach may
well produce convincing models as long as good knowledge of the
relation between coverage and disease prevention exists. This is
true for a measles vaccine, for instance. However, HIV epidemics
are heterogeneous and the relation between coverage and disease
prevention may not be the same in all cultural and epidemiolo-
gical situations.
49 Even with the behaviour-based approach,
knowledge about behaviour change and infections averted is
incomplete. Compared to stable endemic diseases, estimating the
natural history of an increasing or decreasing epidemic is less
straightforward, especially with limited surveillance data.
Infections averted are probably different for different levels of
prevalence, but this often cannot be addressed or is only
addressed in broad ways such as by differentiating by world
regions in either a coverage-based or behaviour-based model. In
stable, endemic situations, the disease modelling-based
approach is simple and convincing, even without a good
understanding of the intervention’s impact on disease and the
overall impact on the population, as long as the disease level
clearly declines in the post-intervention period compared to an
expected level. However, the HIV epidemic continues to evolve.
While a coverage-based approach may be a better tool for
advocacy and planning for an intervention programme, the
disease modelling-based approach is better suited to track the
possible effect of the intervention’s actual implementation.
Is integration of all three approaches a solution? Most
probably it is. However, implementing integration is very
difficult. The reality is far from the ideal owing to various gaps
in data and limited scientific understanding and knowledge on
the complicated and delicate relations between coverage,
behaviour and disease. The Asian epidemic model (AEM) deals
with both disease-related and behaviour-related information.
50 51
It can produce better fitting models to the disease as well as the
underlying behaviour and, consequently, scientifically convin-
cing curves. Therefore, infections averted estimated by compar-
ing two scenarios in the AEM application appear quite
persuasive. However, data requirements are intensive and can
be met successfully by only a few countries—for instance,
Thailand. More extensive data collection should become routine
as recommended by the World Health Organization and
UNAIDS.
52 53 Periodic analysis of collected data for strategic
information purposes facilitates informed decision-making for
programme management as well as evidence-based advocacy.
In conclusion, different types of models can be used to
estimate HIV infections averted, but no model is perfect. We
have delineated one approach here based on an expected
epidemiology and an observed one, a conceptually simple
approach, but some details still need careful consideration and
further research. Moreover, it is important to improve the
breadth and the availability of country level data on various
aspects of the HIV epidemic and refine the models accordingly.
The critical stage is to validate the curves to different country
data sources including HIV prevalence, mortality and beha-
viour. Combining a coverage-based approach with a disease
modelling-based approach is not simple because the two
approaches have different sets of assumptions. Additional
information related to behaviour change may be critical to
have in some situations to further support arguments for a
change in disease trend.
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